Black Diamond Therapeutics
BDTX
74 hedge funds and large institutions have $52.9M invested in Black Diamond Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 26 reducing their positions, and 23 closing their positions.
2% more call options, than puts
Call options by funds: $947K | Put options by funds: $925K
3.86% less ownership
Funds ownership: 63.14% → 59.28% (-3.9%)
15% less funds holding
Funds holding: 87 → 74 (-13)
17% less capital invested
Capital invested by funds: $64.1M → $52.9M (-$11.2M)
48% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 23
54% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$3.31M |
| 2 |
NM
Newtyn Management
New York
|
+$1.21M |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.18M |
| 4 |
Millennium Management
New York
|
+$575K |
| 5 |
E
Ergoteles
New York
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.46M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.04M |
| 3 |
State Street
Boston,
Massachusetts
|
-$681K |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$660K |
| 5 |
JP Morgan Chase
New York
|
-$602K |
BDTX Hedge Fund Activity: Q2 2022 in Review
74 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q2 2022, worth a combined $52.9M — down 17% from $64.1M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of BDTX and 12 opened new positions — a net loss of 11 holders — while 26 trimmed existing stakes and 12 added.
The largest buyer was Bellevue Group, adding an estimated $3.31M. The largest seller was BlackRock, cutting an estimated $2.46M.
- 74 institutional investors held Black Diamond Therapeutics (BDTX) as of Q2 2022, down from 87 in Q1 2022.
- Funds reported $52.9M of Black Diamond Therapeutics stock for Q2 2022, down 17% quarter-over-quarter.
- 12 funds opened new Black Diamond Therapeutics positions in Q2 2022 and 23 closed out, a net change of -11 holders.
- The largest Black Diamond Therapeutics buyer in Q2 2022 was Bellevue Group, an estimated $3.31M added.
- The largest Black Diamond Therapeutics seller in Q2 2022 was BlackRock, an estimated $2.46M sold.
Based on aggregated 13F filings for Q2 2022.